

## Special Issue

# Understanding Diseases Affecting the Central Nervous System

### Message from the Guest Editors

Understanding the intricacies of the varied diseases that affect the central nervous system (CNS) could undoubtedly enable their more effective management. This goal can be achieved through a multidisciplinary approach exploring the intricate interplay between biological, genetic, environmental, and lifestyle factors contributing to CNS disorders. This Special Issue will cover the mechanisms underlying CNS diseases, identifying novel therapeutic strategies and diagnostic biomarkers. Thus, we invite studies that investigate the molecular pathways involved in CNS pathology, assess the efficacy of emerging treatments, explore potential biomarkers for early detection and monitoring, and examine the impacts of lifestyle interventions on disease progression and management. Additionally, studies of the role of neuroinflammation, neuronal plasticity, and neurodegeneration in CNS disorders, as well as investigations into personalized medicine approaches and the development of innovative diagnostic tools, are requested, as these studies help to advance our understanding and management of these complex conditions.

---

### Guest Editors

Dr. Olga Koper-Lenkiewicz

Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Waszyngtona 15A, 15-269 Białystok, Poland

Dr. Joanna Kamińska

Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Waszyngtona 15A, 15-269 Białystok, Poland

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/199289](https://mdpi.com/si/199289)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).